- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01194492
Albumin Kinetics in Generalized Inflammation
Albumin Kinetics in Generalized Inflammation - an Exploratory Study on Patients Before and After Major Abdominal Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Albumin infusions have been used for expansion of the plasma volume for more than 60 years, not only in the operating room, but also in trauma and sepsis. However, there is an ongoing debate whether albumin is good or bad for the patient compared to other intravenous fluids, in different situations. Our research program aims at exploring this issue, starting by describing how the body handles the endogenous albumin in connection with severe inflammation. The final goal is to improve fluid treatment for these patients.
Plasma albumin is often decreased in inflammation. However, the underlying mechanisms are not well described. Two aspects of albumin kinetics will be covered in this study by measurements immediately before and two days after major abdominal surgery, that will serve as a model for generalized inflammation. Albumin fractional synthesis rate will be determined by the incorporation of deuterium labelled phenylalanine into plasma albumin. Albumin distribution will be measured as transcapillary escape rate of radioiodinated albumin. By assessment of P-albumin and plasma volume it will be possible to calculate albumin absolute rate of synthesis and albumin absolute flux from the central compartment, respectively.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, SE-141 86
- Karolinska University Hosptial, Huddinge
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- written informed consent
- patients planned for major abdominal surgery, pancreatic
- age ≥ 40 years
Exclusion Criteria:
- pregnant or lactating patients
- planned peri-operative infusions of albumin or plasma
- S-creatinine > 110 mmol/L
- allergy against iodine
- other conditions preventing the subject from participating in the study, as judged by the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
OTHER: Albumin kinetics
|
Repeated measure by injection of 0.1 megabecquerel and 0.3 megabecquerel of 125-iodine labeled albumin before surgery and 2 days after surgery, respectively.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in albumin transcapillary escape rate
Time Frame: 2 days
|
Transcapillary escape rate is measured as the rate of decrease of 125I-albumin in plasma over 90 min.
The assessment is performed twice, immediately before surgery and in the second post-operative day, respectively.
|
2 days
|
|
Change from baseline in albumin synthesis rate
Time Frame: 2 days
|
2 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes from baseline in markers of inflammation (heart rate, respiratory rate, body temperature, Blood leukocyte count, and P-CRP)
Time Frame: 2 days
|
The markers of inflammation is measured twice in each patient, immediately before and two days after surgery, respectively.
|
2 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Sigridur Kalman, MD, Ass Prof, Karolinska Institutet, Institution of Clinical Science Intervention and Technology, Dept of Anesthesiology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010-018529-21
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Abdominal Surgery
-
York Teaching Hospitals NHS Foundation TrustCompletedColorectal Surgery | Major Abdominal SurgeryUnited Kingdom
-
The Cleveland ClinicCompletedMajor Abdominal SurgeryUnited States
-
Alexandria UniversityRecruiting
-
University Hospital, Clermont-FerrandUniversity Hospital, Montpellier; Rennes University HospitalCompleted
-
ghada fouadCompletedMajor Abdominal SurgeryEgypt
-
Erasme University HospitalCompletedMajor Abdominal SurgeryBelgium
-
University Hospital OstravaCompletedMajor Abdominal SurgeryCzech Republic
-
Enrique Alday MuñozCompleted
-
Centre Hospitalier Universitaire de NīmesWithdrawnMajor Abdominal SurgeryFrance
-
Hospital Universitario La PazUniversity of Valencia; Carmel Medical Center; Hospital del Rio Hortega; Hospital... and other collaboratorsCompleted
Clinical Trials on Albumin transcapillary escape rate (125I-albumin)
-
Zealand University HospitalCompleted
-
Boston Scientific CorporationCompletedHepatocellular CarcinomaUnited States
-
Tanta UniversityAin Shams UniversityCompleted
-
Hospital Clinic of BarcelonaCompleted
-
Shandong Cancer Hospital and InstituteCancer Hospital Chinese Academy of Medical ScienceNot yet recruiting
-
AstraZenecaDaiichi SankyoActive, not recruitingAdvanced or Metastatic Breast CancerUnited States, Belgium, Canada, Denmark, France, Italy, Spain, Hungary, Taiwan, Germany, Brazil, Mexico, Poland, United Kingdom, China, Israel, Austria, Australia, Japan, Saudi Arabia, Netherlands, India, Argentina, Sweden, Singapore, Por... and more
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage II Breast Cancer AJCC v8 | Prognostic Stage IIA Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer... and other conditionsUnited States, Puerto Rico
-
Assiut UniversityUnknownInflammatory Bowel Diseases | Vitamin D DeficiencyEgypt
-
Poznan University of Medical SciencesCompletedCardiovascular Diseases | Inflammation | Chronic Kidney Diseases | Dialysis; Complications | Atherosclerosis of ArteryPoland